Research Comparison
CJC-1295 (without DAC) vs Tesamorelin
A side-by-side research comparison of CJC-1295 (without DAC) and Tesamorelin drawn from Cobalt Peptides' peptide database records.
CJC-1295 (without DAC)
CJC-1295 (without DAC), also known as Modified GRF 1-29 (Mod GRF 1-29), is a short-acting synthetic analog of growth hormone releasing hormone (GHRH). It is designed to stimulate endogenous growth hormone (GH) release in a pulsatile, physiologically consistent manner. Unlike the DAC-modified version, this variant has a very short half-life, allowing precise control over GH pulses and reducing the risk of receptor desensitization. It is primarily used in research focused on recovery, anti-aging, body composition, and endocrine function optimization.
Tesamorelin
Tesamorelin is a synthetic analogue of growth hormone-releasing hormone (GHRH), a 44-amino acid peptide carrying a trans-3-hexenoic acid modification at the N-terminus that confers resistance to enzymatic degradation. It binds the GHRH receptor, and the published literature describes pulsatile growth hormone release and downstream IGF-1 elevation. A licensed medicine containing tesamorelin exists in some jurisdictions and is prescribed by clinicians; the material supplied here is a research compound and is not that medicine.